Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Efficacy Study of Tranilast in Patients With Active Rheumatoid Arthritis (RA)

This study has been completed.
Sponsor:
Information provided by:
Nuon Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT00882024
First received: April 14, 2009
Last updated: January 5, 2011
Last verified: January 2011

April 14, 2009
January 5, 2011
March 2009
December 2010   (final data collection date for primary outcome measure)
Proportion of subjects who achieve of ACR20 response [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00882024 on ClinicalTrials.gov Archive Site
  • Proportion of subjects achieving ACR 50 and 70 response [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
  • EULAR responders (e.g. DAS28 good or moderate responders) [ Time Frame: week 12 ] [ Designated as safety issue: No ]
  • Mean change from baseline of each ACR component [ Time Frame: weeks 2, 4, 8, 12 and 16 ] [ Designated as safety issue: No ]
  • Assess the safety and tolerability of both doses of tranilast [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Safety and Efficacy Study of Tranilast in Patients With Active Rheumatoid Arthritis (RA)
A Phase II, Randomized Multi-Center, Double-Blind Study of Tranilast With Concomitant Methotrexate (MTX) Compared to MTX Alone in Patients With Active Rheumatoid Arthritis (RA)

The purpose of this study is to evaluate whether tranilast at two different dosages compared to placebo is effective in patients with active RA when added to continuing methotrexate (MTX) therapy.

The primary objective of this study is to assess the efficacy and safety of two different doses of tranilast as determined by ACR20 response at 12 weeks.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Active Rheumatoid Arthritis
  • Drug: Tranilast
    150 mg tranilast tablets, bid, 12 weeks
  • Drug: Tranilast
    75 mg tablets, bid, 12 weeks
  • Drug: Placebo
    Placebo tablets, bid, 12 weeks
  • Experimental: 1 Tranilast
    Tranilast, 300 mg/day
    Intervention: Drug: Tranilast
  • Experimental: 2 Tranilast
    Tranilast, 150 mg/day
    Intervention: Drug: Tranilast
  • Placebo Comparator: 3
    Placebo
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
250
December 2010
December 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Receiving methotrexate
  • Have at least 8 painful/tender and 6 swollen joints
  • May be receiving oral steroids, chronic NSAIDs and/or hydroxychloroquine.

Exclusion Criteria:

  • Use of any anti-arthritic treatments except those allowed in inclusion criteria
  • Pregnant or nursing females
  • Abnormal laboratory values
  • History of clinically significant renal, hepatic dysfunction, psychiatric disorder, or alcohol/drug dependence
  • Clinically significant systemic infection
Both
18 Years to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
United States,   Argentina,   Bulgaria,   Czech Republic,   Germany,   Mexico,   Serbia,   United Kingdom
 
NCT00882024
A3003RA
Yes
Michael Kitt, MD/Chief Medical Officer, Nuon Therapeutics, Inc.
Nuon Therapeutics, Inc.
Not Provided
Study Director: Michael Kitt, MD Nuon Therapeutics, Inc.
Nuon Therapeutics, Inc.
January 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP